Refuge Biotechnologies, Inc.

Executive changes in the off-patent medicines industry throughout 2023 reflected a growing interest in the innovator side of the life sciences sector among leading generics and biosimilars companies.

In 2023, Viatris Inc. continued its efforts to pivot from off-patent products toward innovative operations, offloading four of its businesses including its six-facility-strong active pharmaceutical

Gilead ’s cell therapy division Kite has signed a deal with a synthetic biology company Refuge Biotechnologies to help it to develop a next generation of CAR-T therapies. Kite is a leader in the f

Bristol, Evotec Tap Researchers In Birmingham, Edinburgh, Nottingham, Dundee Evotec SE and Bristol Myers Squibb Company will collaborate with researchers at four UK universities on identifying pot